Seyer Yasser S. H.
- Country
- Germany
- Department
- Bad Homburg
Research Overview
- Efficacy and Safety of MET097 in Adults with Overweight or Obesity: A Phase 3, Randomized, Placebo-Controlled Trial
- Effect of Muvalaplin on Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: A Phase 3 Randomized Trial
- Evaluation of Obicetrapib on Major Adverse Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients on Maximal Lipid-Modifying Therapy
Data & Insights
Has run more than one trial at 729 of 1519 partner sites.
Specializations
Atherosclerotic cardiovascular disease and lipid management
Clinical research activity centers on atherosclerotic cardiovascular disease, established cardiovascular disease, and high-risk lipid disorders, with particular attention to LDL-C reduction, hypercholesterolemia, hyperlipidemia, and broader lipoprotein disorder care. The trial portfolio also includes interest in elevated lipoprotein(a) and prevention of recurrent cardiovascular events.
- Elevated lipoprotein(a) and Lp(a)-targeted therapy
- LDL cholesterol lowering strategies
- Major adverse cardiovascular events
Research involvement reflects a strong therapeutic focus on cardiovascular risk reduction and lipid-modifying innovation in patients with pre-existing vascular disease.
Hypertension and blood pressure control
Another major area of interest is hypertension, including resistant hypertension, uncontrolled hypertension, and treatment-resistant blood pressure elevation in patients with additional cardiometabolic risk. The clinical landscape also extends to blood pressure management in the setting of chronic kidney disease and established cardiovascular disease.
- Resistant hypertension
- Uncontrolled hypertension
- Ambulatory and seated systolic blood pressure
The investigator’s work includes therapeutic interest in novel antihypertensive approaches for patients with complex cardiovascular and renal profiles.
Obesity, overweight, and chronic weight management
Clinical trial involvement includes obesity, overweight, and chronic weight management, with studies linking weight reduction to cardiovascular and metabolic outcomes. This area also overlaps with cardiometabolic prevention in individuals with elevated cardiovascular risk.
- Body weight reduction
- Overweight-related cardiovascular risk
- Cardiometabolic disease prevention
Therapeutic interest extends to obesity-related interventions that may influence long-term cardiovascular and metabolic health.
Type 2 diabetes, chronic kidney disease, and cardiorenal protection
Research activity includes type 2 diabetes, chronic kidney disease, and combined cardiorenal risk, particularly in participants with hypertension and cardiovascular disease. The portfolio reflects interest in outcomes related to renal preservation, heart failure prevention, and cardiovascular event reduction.
- Cardiorenal disease
- Kidney function preservation
- Heart failure prevention
This area highlights therapeutic engagement with conditions where renal and cardiovascular complications intersect.
Atrial fibrillation and heart failure prevention
The investigator is also involved in studies of atrial fibrillation and prevention of heart failure, with clinical interest in reducing cardioembolic and heart failure-related risk among patients with broader cardiovascular disease burden.
- Atrial fibrillation burden
- Cardioembolic event prevention
- Heart failure risk reduction
These research areas align with therapeutic efforts aimed at limiting arrhythmic complications and downstream cardiovascular events.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.